自動車運転者における特定の神経病理学的状態の早期発見 (NeuroDrive)
自動車運転者における特定神経病理学的状態の早期検出
調査の概要
詳細な説明
この研究は2つのフェーズで実施されます。 まず、健康な参加者のコホートがウィーン・テスト・システム(VTS)を用いて評価を受けます。 その後、多発性硬化症(MS)またはパーキンソン病(PD)と診断された個人からなる臨床コホートを募集します。 各臨床参加者は、モントリオール認知評価(MoCA)、25フィート歩行テスト(25-FWT)、記号数字様式テスト(SDMT)、およびナインホール・ペグテスト(9-HPT)を含む基本的な神経学的検査を完了します。 その後、彼らはVTSテストを受けます。
PD患者はホーン・ヤール尺度に従って分類され、MS患者は拡張障害状態尺度(EDSS)を使用してステージングされます。 目的は、VTSの結果と最も強い相関を示す、容易にアクセス可能な臨床テストを特定し、運転者の標準的な医学的評価に組み込むことができる信頼性の高いマーカーを同定することです。
第2フェーズでは、この研究の範囲外で得られた臨床補助的所見を使用して、エビデンス基盤を強化します。 最終的に、このプロジェクトは、医師が患者の運転適性を評価する際に使用できる実用的な計算機の形でリスク方程式を提案することを目指しています。 追加の期待される成果として、神経病理を有する運転者が安全な運転能力を維持または向上させるための、ターゲットを絞った認知および運動トレーニング介入の開発が挙げられます。
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Ladislav Stanke, Ph.D.
- 電話番号:+420 588 443 713
- メール:Ladislav.Stanke@fnol.cz
研究連絡先のバックアップ
- 名前:Dalibor Zimek, M.D.
- 電話番号:+420 702 048 036
- メール:Dalibor.Zimek@fnol.cz
研究場所
-
-
Olomouc Region
-
Olomouc、Olomouc Region、チェコ、779 00
- 募集
- University Hospital Olomouc
-
コンタクト:
- Ladislav Stanke, Ph.D.
- 電話番号:+420 588 443 713
- メール:Ladislav.Stanke@fnol.cz
-
コンタクト:
- Dalibor Zimek, M.D.
- 電話番号:+420 702 048 036
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
包含基準:
- インフォームド・コンセントに署名した後の方。
- 指定された神経学的診断の有効な診断基準を満たした後。
- 有効な運転免許証と、現在運転していることの証明を所持していること。
- 年齢制限は18歳から85歳まで。
除外基準:
- 現在の心理学的検査(MMSE24点以下)に基づく認知症の確定診断。
- チェコ法第277/2004号(改正版、特に第204/2025号法)に基づく自動車運転適性に関する法律によると、自動車を安全に運転する能力を妨げる、または著しく制限する疾病または状態の診断(例:認知症、てんかん、重度の意識障害)。
- 年齢が18歳未満。
- 年齢が85歳を超える。
- 第二のコホート(多発性硬化症患者)において、研究参加前の過去6週間以内に確認され治療された再発。
- MSコホートにおいて、現在のEDSSスコアが6.5点を超える。
- PDコホートにおいて、現在のHoehn and Yahrスケールのスコアが4以上。
- 両コホートにおいて、検査室検査により示された感染随伴性悪化の証拠。
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Parkinson disease cohort
PD patients cohort will consist of 100 patients with parkinson disease aged between 18-85 years, with, with a balanced sex distribution to ensure representativeness and reduce gender bias.
The target sample size (N = 100) has been chosen to provide adequate statistical power to detect moderate to strong correlations between clinical and paraclinical measures, it is intended to acquire a regular distribution across all age groups .
Participants with premorbid cognitive impairment or those not clinically stable during the study period will be excluded, also participants with a Hoehn and Yahr stage greater than 4 will be excluded.
|
|
Multiple sclerosis cohort
Multiple sclerosis patient cohort will consist of 100 patients with multiple sclerosis.
aged between 18-85 years, with, with a balanced sex distribution to ensure representativeness and reduce gender bias.
The target sample size (N = 100) has been chosen to provide adequate statistical power to detect moderate to strong correlations between clinical and paraclinical measures, it is intended to acquire a regular distribution across all age groups.
Participants with premorbid cognitive impairment or those not clinically stable during the study period will be excluded also an Expanded Disability Status Scale (EDSS) score above 6.5 will serve as an exclusion criterion.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Vienna Test Systems (VTS) - Determination Test (DT)
時間枠:Day 1
|
Vienna Test System (VTS) - Determination Test (DT). A computerized test of attention, stress tolerance, and psychomotor reactivity under complex conditions. Participants are presented with rapidly changing visual and auditory stimuli (e.g., colored lights, acoustic signals) and must respond as quickly as possible using multiple response keys or pedals. Scoring: outcomes include mean and median reaction time (ms), number of correct responses, omission errors (missed stimuli), commission errors (incorrect responses), and measures of performance stability across the task. Faster, more accurate, and stable performance indicates better attentional control and stress tolerance. Administration: conducted in a quiet environment with standardized VTS hardware and software. Trained staff provide uniform instructions and monitor performance. |
Day 1
|
|
Vienna Test Systems (VTS) - Reaction Test (RT)
時間枠:Day 1
|
Vienna Test System (VTS) - Reaction Test (RT). A computerized assessment of simple and choice reaction time measuring perceptual speed and motor response. Participants are presented with visual and/or auditory stimuli and instructed to respond as quickly as possible by pressing a button (simple RT) or selecting the correct response among multiple options (choice RT). Scoring: main outcomes include mean reaction time (ms), number of correct responses, and error rates. Faster and more accurate responses indicate better psychomotor speed and attention. Separate scores are calculated for simple and choice conditions. Administration: conducted individually in a quiet, distraction-free environment using standardized VTS hardware and software. Trained staff provide standardized instructions and supervise. |
Day 1
|
|
Vienna Test Systems (VTS) - Response inhibition (INHIB)
時間枠:Day 1
|
Vienna Test System (VTS) - Response Inhibition (INHIB). A computerized go/no-go paradigm measuring impulse control and inhibitory executive function. Participants are presented with a continuous sequence of visual stimuli on screen. They are instructed to respond via button press to "go" stimuli and withhold responses to "no-go" stimuli. Scoring: main outcomes include reaction time to go-stimuli, number of correct responses (hits), commission errors (responses to no-go stimuli), and omission errors (missed go-stimuli). Higher accuracy with fewer commission errors reflects better inhibitory control. Administration: conducted individually in a distraction-free environment using standardized VTS software and response panel. Trained staff provide instructions and supervise performance. |
Day 1
|
|
Vienna Test Systems (VTS) - Vigilance/Sustained attention (WAFV) - Short version
時間枠:Day 1
|
Vienna Test System (VTS) - Vigilance/Sustained Attention (WAFV). A computerized test measuring sustained attention and vigilance. Participants monitor a continuous sequence of simple visual stimuli (e.g., small changes in geometric figures) presented at regular intervals. They are instructed to respond via button press whenever a predefined critical stimulus appears. Scoring: main outcomes include number of correct detections (hits), omissions (missed targets), false alarms (incorrect responses), and reaction times. Higher hits and faster, stable reaction times indicate better vigilance; higher omissions or false alarms indicate poorer sustained attention. Administration: conducted individually in a distraction-free environment using the standardized VTS software and response panel. Trained staff provide instructions and supervise. |
Day 1
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Montreal Cognitive Assessment (MoCA)
時間枠:Day 1
|
Montreal Cognitive Assessment (MoCA). A clinician-administered screening tool for mild cognitive impairment covering multiple domains: attention, concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The test consists of 30 items with a maximum total score of 30; higher scores = better cognition. A score of 26 or above is considered normal. If the participant has ≤12 years of formal education, +1 point is added. Administration: conducted face-to-face in a quiet environment by trained staff using validated language versions; completion requires ~10-15 minutes. Outcomes: total score and change from baseline. |
Day 1
|
|
25-Foot Walk Test (25-FWT)
時間枠:Day 1
|
25-Foot Walk Test (25-FWT). A quantitative measure of ambulatory function and walking speed. Participants are instructed to walk 25 feet (7.62 m) as quickly and safely as possible. Two trials are performed, typically with a short rest interval, and the average time (in seconds) is recorded using a stopwatch. Lower times = better mobility. Use of customary assistive devices (e.g., cane, walker) is permitted and documented. Administration: conducted in a straight, unobstructed corridor with clearly marked start and finish lines. Trained staff provide standardized instructions and supervise for safety. Completion typically requires ~5 minutes. Outcomes: average time to walk 25 feet (7.62 meters), ability to complete the test, and change from baseline. |
Day 1
|
|
Symbol Digit Modalities Test (SDMT)
時間枠:Day 1
|
Symbol Digit Modalities Test (SDMT). A brief neurocognitive test of attention, processing speed, and visual scanning. Participants are shown a key pairing nine symbols with digits 1-9. Using this key, they write or orally state the digit corresponding to each symbol in a randomized sequence presented on the test form. Scoring: the number of correct substitutions completed in 90 seconds is counted. Higher scores = better cognitive performance. Errors are recorded but not included in the raw score. Written and oral versions are available; the same mode is used across visits for consistency. Administration: conducted in a quiet environment with standardized instructions, requiring ~5 minutes. Staff monitor to ensure task adherence. Outcomes: total correct substitutions and standard deviation change from the normal value. |
Day 1
|
|
Nine-Hole Peg Test (9-HPT)
時間枠:Day 1
|
Nine-Hole Peg Test (9-HPT). A standardized test of finger dexterity and fine motor function. Participants are instructed to place nine pegs into nine holes on a board, one at a time, as quickly as possible, and then remove them. Each hand is tested separately, typically with the dominant hand first, followed by the non-dominant hand. Scoring: performance time (in seconds) for each hand is recorded with a stopwatch. Lower times = better dexterity. Two consecutive trials per hand are averaged. If a peg is dropped, the participant retrieves it and continues. Administration: administered in a quiet environment by trained staff using standardized instructions. Completion time is usually 3-5 minutes for both hands. Outcomes: mean completion time for each hand and change from baseline. |
Day 1
|
|
Benton Visual Retention Test (BVRT)
時間枠:Day 1
|
A neuropsychological assessment of visual memory, perception, and visuoconstructive ability. Participants are shown a series of 10 geometric designs, each displayed for 10 seconds, and then asked to reproduce the design from memory using paper and pencil (Administration A). Alternate forms may be used to minimize practice effects. Scoring: each reproduction is scored for number correct (maximum = 10) and for errors (e.g., omissions, distortions, rotations, perseverations, misplacements). Higher correct scores indicate better performance, while higher error counts indicate impairment. Administration: conducted individually in a quiet setting by trained staff; typical completion ~15 minutes. Outcomes: total correct responses, total errors, and change from baseline. |
Day 1
|
|
The Big Five Inventory-2 Short Form (BFI-2-S)
時間枠:Day 1
|
Big Five Inventory-2 Short Form (BFI-2-S). A 30-item self-report assessing five personality domains: Extraversion, Agreeableness, Conscientiousness, Negative Emotionality, and Open-Mindedness. Items are rated on a 5-point Likert scale (1 = disagree strongly to 5 = agree strongly). For each domain, compute the mean of its 6 items after applying the manual's reverse-keying rules; higher scores = more of that trait. No total score is used. Administration: validated language version via paper or secure ePRO; typical completion ~5-7 min. Staff provide standardized instructions and check completeness. Outcomes: domain scores (1-5) and change from baseline. Timing: baseline and follow-ups within ±3 days of the visit window. |
Day 1
|
|
Epworth Sleepiness Scale (ESS)
時間枠:Day 1
|
An 8-item self-report of daytime sleepiness. Participants rate their chance of dozing in common situations from 0 (would never doze) to 3 (high chance). Total score = sum of items (range 0-24; higher = worse sleepiness). Severity bands: 0-5 normal, 6-10 higher-than-normal, 11-12 mild, 13-15 moderate, 16-24 severe. Administration: validated language version via paper or secure ePRO; typical completion ~2-3 min. Staff provide standardized instructions and check completeness before scoring. Outcomes: total score; change from baseline; response = ≥3-point reduction from baseline; remission = score ≤10. |
Day 1
|
|
Beck's Depression Inventory (BDI-II)
時間枠:Day 1
|
A 21-item self-report questionnaire assessing depressive symptoms over the past 2 weeks, including today.
Each item is rated 0-3; total score ranges 0-63, with higher scores indicating more severe depression.
Severity categories: 0-13 minimal, 14-19 mild, 20-28 moderate, 29-63 severe.
The BDI-II is administered in validated language versions on paper or secure ePRO, requiring ~5-10 minutes.
Staff provide standardized instructions and check completeness.
Outcomes include total score, change from baseline, response (≥50% reduction from baseline), and remission (score ≤13).
|
Day 1
|
|
Driving experience self-evaluation questionnaire
時間枠:Day 1
|
This self-report questionnaire captures recent driving exposure and perceived difficulties over the past month.
Items use 7-point Likert scales anchored "Never (1)" to "Every drive (7)".
Content includes deliberate avoidance of challenging conditions (night driving, heavy traffic, bad weather, highways, unfamiliar routes), fatigue while driving, uncertainty in traffic situations (e.g., speed limits, lane selection, right of way), perceived complexity/overload, inattention, vehicle-control errors (e.g., wrong gear, pedal mix-ups), oversight errors (e.g., missed lights/signs, failure to check mirrors), warnings from other road users, risk-taking, traffic-rule violations, and emotional arousal during driving.
A brief exposure module records typical driving frequency, lifetime kilometers, and the frequency of driving in specific conditions.
Higher scores indicate more frequent difficulties; the primary metric is the mean item score (1-7).
|
Day 1
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- OP JAK ITI VZ 1
- CZ.02.01.01/00/23_021/0008829 (その他の助成金/資金番号:Operational Programme Jan Ámos Komenský financed by the European Union (EU) and the State Budget of Czech Republic)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。